Mechanical Compatibility Is the New Biocompatibility: A Process View of Implant Success

Abstract

Implant science has traditionally treated “biocompatibility” as the master criterion of success, focusing on cytotoxicity, corrosion, immune response, infection control, and the chemical stability of materials in vivo. However, many clinically “biocompatible” devices still fail at the point where the body actually meets the device: the mechanical interface. The interface is not a passive boundary. It is a living, adapting, mechanosensitive microenvironment in which cells integrate stiffness, micromotion, surface roughness, fluid shear, and wear debris with biochemical signals to decide whether to incorporate an implant, wall it off, resorb adjacent tissue, or trigger chronic inflammation. In load-bearing orthopaedics, stiffness mismatch produces stress shielding and maladaptive remodelling; excessive micromotion drives fibrous encapsulation rather than osseointegration; abrasive wear creates particulates that sustain macrophage activation and osteolysis; and design choices that are mechanically adequate in bench tests can still fail in vivo when the implant–tissue system evolves. In soft-tissue implantation, substrate stiffness can be a primary driver of the foreign body response and fibrotic capsule formation through mechanosensitive pathways, such as TRPV4-mediated macrophage–fibroblast signalling. Mechanical compatibility is not a replacement for classical biocompatibility; rather, it should be treated as a co-equal, first-class design requirement in mechanosensitive organisms. Chemically biocompatible materials can still fail through stiffness mismatch, micromotion, fretting and wear debris generation, and mechanobiology-driven fibrosis or osteolysis. We therefore propose a process view of implant success: tissue mechanics should be measured in clinically relevant states, transformed into constitutive models and interface performance envelopes, translated into explicit mechanical-compatibility specifications, and then realised through manufacturing process windows that can reliably reproduce targeted architectures and surface states. Additive manufacturing and microstructural engineering enable the tuning of modulus, the formation of porosity gradients, and the generation of patient-specific compliance fields, but these advances only improve outcomes when coupled to metrology, statistical process control, and validation loops that close the gap between intended and realised interface mechanics through clinical surveillance.